


Midazolam SOP

PGD

Further reading

<https://bnf.nice.org.uk/drug/midazolam.html>
NICE guideline - Convulsive status epilepticus 2004/2011
GNAAS Midazolam PGD



Indications

- i) Continuation of sedation following PHEA - **HEMS Team Only**
- ii) Prevention or treatment of ketamine-induced agitation
- iii) Sedation
- iv) Status epilepticus

Effects and side-effects

A benzodiazepine which causes sedation, anxiolysis, amnesia and acts as an anticonvulsant. Cardiorespiratory depressant effects which may lead to hypotension and a reduced respiratory drive/apnoea.

Presentation

A clear and colourless solution in ampoules containing 10mg in 2mls for intravenous injection. May also be given by the intraosseous, intranasal, buccal or intramuscular routes in the emergency setting.



Midazolam SOP

PGD

Administration

Sedation following PHEA

In conjunction with morphine, titrated to effect depending on patient physiology. Usual dose range 0.01-0.05mg/kg every 10mins.

Acute Sedation

As a sole agent, **titrated IV/IO** to effect depending on patient physiology. Usual dose range 0.01-0.05mg/kg, repeated as required.

IM bolus dose - 50-100mcg/kg repeated as required

To prevent or treat unpleasant dysphoric effects caused by ketamine - 0.02mg/kg, repeated as required.

Status epilepticus

Buccal - Adults 10mg, repeated once if required
- Children 0.5mg/kg (max 10mg), repeated once if required

OR

Intravenous/IO - All ages: 0.05mg/kg, repeated once if required

Contraindications

In the context of the emergency presentations likely to be encountered by GNAAS, the only absolute contraindication is known anaphylaxis to midazolam.